Benzinga | Dec 16, 2021 07:08AM EST

IN8bio Provides Update From The Ongoing Phase 1 Clinical Trial Of Its Allogeneic Gamma-Delta T Cell Therapy In Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant



* The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients

* 3 patients have been treated to date, all of whom remain in remission with the first two patients at ~20 months and ~18 months post treatment, respectively, and the most recent at ~6 months

* Of the 3 patients that were dosed with INB-100, all have achieved and remain in remission to date, durable responses of >1.5 years were observed in two patients

* INB-100 continues to demonstrate a manageable safety profile to-date, with no dose-limiting toxicities, no treatment-related grade 3 or greater adverse events, and no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)